Kanghongbei: Subsidiary JiKetokoko Alkaline Sustained-Release Tablets Obtained Drug Registration Certificate.

Kanghongbei announcement, its wholly-owned subsidiary Hangzhou Kanghongbei has received the "Drug Registration Certificate" issued by the National Medical Products Administration for the ketoprofen sustained-release tablets. The original research enterprise of this drug is Sanofi-aventis, and it is indicated for peripheral vascular diseases, including intermittent claudication and rest pain. Hangzhou Kanghongbei submitted the drug registration application in December 2024 and has invested approximately 10.09 million yuan in research and development expenses. According to the National Medical Products Administration Drug Evaluation Center website, as of the date of this announcement, a total of 16 domestic manufacturers, including Hangzhou Kanghongbei, have been approved for the registration application of ketoprofen sustained-release tablets as Class 3 chemical drugs.